BioFIT is sponsored by companies from across the Life Sciences sector, reflecting the breadth of the event’s content, participants and partners.
Be one of them, contact us for further details.
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide… and many of these advances were the result of partnerships. In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.
Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Our significant investment in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor* in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4™ technology has been licensed to LabCorp® in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. Nasdaq and Euronext: GNFT.
* Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority
Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. We are committed to the discovery and development of innovative treatments for diabetes, obesity, haemophilia, NASH, atherosclerosis, heart failure, chronic kidney disease and we are seeking partnerships in all these indications. From molecule to market, our focus is on the patient. We are also committed to environmental and social responsibility.